BeStock  

BioCryst Pharmaceuticals BCRX

US equityMarket cap rank #2720Drug Manufacturers - Specialty & Generic
$7.22 −$0.10 (-1.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $7.10 -1.66%
Open$7.26
Prev close$7.32
Day range$7.15 – $7.39
Volume3.85M
Market cap$1.86B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±8.2%last 16 reports
Closed higher9 of 1656% of the time
Best reaction+23.5%
Worst reaction-15.3%

Stock move on the day after each report

+1.4%2023/Q4+18.4%2024/Q1+7.0%2024/Q2-12.8%2024/Q3-10.0%2024/Q4+23.5%2025/Q1+9.8%2025/Q2-6.3%2025/Q3+4.6%2025/Q4-2.2%2026/Q1+0.6%2026/Q2-3.9%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q34 Nov 2026Pre Market±15.4%-3.85%Within range
2026/Q25 Aug 2026Pre Market±11.9%+0.55%Within range
2026/Q16 May 2026Pre Market±10.5%-2.21%Within range
2025/Q426 Feb 2026Pre Market±8.7%+4.64%Within range
2025/Q33 Nov 2025Pre Market±16.4%-6.28%Within range
2025/Q24 Aug 2025None±16.9%+9.81%Within range
2025/Q15 May 2025None±11.7%+23.52%Bigger than priced
2024/Q424 Feb 2025Pre Market±15.8%-9.99%Within range
2024/Q34 Nov 2024None±15.1%-12.81%Within range
2024/Q25 Aug 2024Pre Market±17.0%+6.98%Within range
2024/Q16 May 2024Pre Market±17.5%+18.43%Bigger than priced
2023/Q426 Feb 2024None±24.3%+1.40%Within range
2023/Q32 Nov 2023Pre Market±16.4%-1.57%Within range
2023/Q23 Aug 2023Pre Market±15.2%+1.87%Within range
2023/Q13 May 2023Pre Market±14.9%+12.48%Within range
2022/Q421 Feb 2023Pre Market±14.6%-15.29%Bigger than priced

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q3, ended Sep 2026

Revenue$180.29M+13.1% YoY
Operating profit$53.33M+80.2% YoY
Net profit$37.92M+193.9% YoY
Diluted EPS$0.14+133.3% YoY
Free cash flow$32.75M-18.7% YoY
Operating cash flow$32.98M

Revenue, last 8 quarters

$131.5MDec '24$145.5MMar '25$163.4MJun '25$159.4MSep '25$406.6MDec '25$156.4MMar '26$218.3MJun '26$180.3MSep '26

Net profit, last 8 quarters

$-26.8MDec '24$32.0KMar '25$5.1MJun '25$12.9MSep '25$245.8MDec '25$-721.8MMar '26$78.4MJun '26$37.9MSep '26

Profitability & balance sheet

Gross margin97.9%
Operating margin42.5%
Net margin-37.4%
Return on assets-69.3%
Current ratio2.71
Liabilities / assets167.2%
Cash & investments$375.00M
Total debt$781.01M
Net cash (debt)-$406.01M
Free cash flow / sales38.0%

Discussion

No comments yet — be the first to weigh in on BCRX.

Sign in to join the discussion.

Scroll to Top